Copyright Reports & Markets. All rights reserved.

Global Prostate Cancer Antigen 3 Test Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Prostate Cancer Antigen 3 Test by Type
    • 1.3.1 Overview: Global Prostate Cancer Antigen 3 Test Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Prostate Cancer Antigen 3 Test Consumption Value Market Share by Type in 2023
    • 1.3.3 RT-PCR
    • 1.3.4 ELISA Test
  • 1.4 Global Prostate Cancer Antigen 3 Test Market by Application
    • 1.4.1 Overview: Global Prostate Cancer Antigen 3 Test Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Diagnosis Center
    • 1.4.4 Other
  • 1.5 Global Prostate Cancer Antigen 3 Test Market Size & Forecast
  • 1.6 Global Prostate Cancer Antigen 3 Test Market Size and Forecast by Region
    • 1.6.1 Global Prostate Cancer Antigen 3 Test Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Prostate Cancer Antigen 3 Test Market Size by Region, (2019-2030)
    • 1.6.3 North America Prostate Cancer Antigen 3 Test Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Prostate Cancer Antigen 3 Test Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Prostate Cancer Antigen 3 Test Market Size and Prospect (2019-2030)
    • 1.6.6 South America Prostate Cancer Antigen 3 Test Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Hologic
    • 2.1.1 Hologic Details
    • 2.1.2 Hologic Major Business
    • 2.1.3 Hologic Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.1.4 Hologic Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Hologic Recent Developments and Future Plans
  • 2.2 Thermo Fisher Scientific
    • 2.2.1 Thermo Fisher Scientific Details
    • 2.2.2 Thermo Fisher Scientific Major Business
    • 2.2.3 Thermo Fisher Scientific Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.2.4 Thermo Fisher Scientific Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.3 MDxHealth
    • 2.3.1 MDxHealth Details
    • 2.3.2 MDxHealth Major Business
    • 2.3.3 MDxHealth Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.3.4 MDxHealth Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 MDxHealth Recent Developments and Future Plans
  • 2.4 Exosome Diagnostics GmbH
    • 2.4.1 Exosome Diagnostics GmbH Details
    • 2.4.2 Exosome Diagnostics GmbH Major Business
    • 2.4.3 Exosome Diagnostics GmbH Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.4.4 Exosome Diagnostics GmbH Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Exosome Diagnostics GmbH Recent Developments and Future Plans
  • 2.5 Copyright Creative Diagnostics
    • 2.5.1 Copyright Creative Diagnostics Details
    • 2.5.2 Copyright Creative Diagnostics Major Business
    • 2.5.3 Copyright Creative Diagnostics Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.5.4 Copyright Creative Diagnostics Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Copyright Creative Diagnostics Recent Developments and Future Plans
  • 2.6 Lytech
    • 2.6.1 Lytech Details
    • 2.6.2 Lytech Major Business
    • 2.6.3 Lytech Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.6.4 Lytech Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Lytech Recent Developments and Future Plans
  • 2.7 YUBO
    • 2.7.1 YUBO Details
    • 2.7.2 YUBO Major Business
    • 2.7.3 YUBO Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.7.4 YUBO Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 YUBO Recent Developments and Future Plans
  • 2.8 MicroDiag Biomedicine
    • 2.8.1 MicroDiag Biomedicine Details
    • 2.8.2 MicroDiag Biomedicine Major Business
    • 2.8.3 MicroDiag Biomedicine Prostate Cancer Antigen 3 Test Product and Solutions
    • 2.8.4 MicroDiag Biomedicine Prostate Cancer Antigen 3 Test Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 MicroDiag Biomedicine Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Prostate Cancer Antigen 3 Test Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Prostate Cancer Antigen 3 Test by Company Revenue
    • 3.2.2 Top 3 Prostate Cancer Antigen 3 Test Players Market Share in 2023
    • 3.2.3 Top 6 Prostate Cancer Antigen 3 Test Players Market Share in 2023
  • 3.3 Prostate Cancer Antigen 3 Test Market: Overall Company Footprint Analysis
    • 3.3.1 Prostate Cancer Antigen 3 Test Market: Region Footprint
    • 3.3.2 Prostate Cancer Antigen 3 Test Market: Company Product Type Footprint
    • 3.3.3 Prostate Cancer Antigen 3 Test Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Prostate Cancer Antigen 3 Test Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Prostate Cancer Antigen 3 Test Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Prostate Cancer Antigen 3 Test Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Prostate Cancer Antigen 3 Test Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Prostate Cancer Antigen 3 Test Consumption Value by Type (2019-2030)
  • 6.2 North America Prostate Cancer Antigen 3 Test Market Size by Application (2019-2030)
  • 6.3 North America Prostate Cancer Antigen 3 Test Market Size by Country
    • 6.3.1 North America Prostate Cancer Antigen 3 Test Consumption Value by Country (2019-2030)
    • 6.3.2 United States Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Prostate Cancer Antigen 3 Test Consumption Value by Type (2019-2030)
  • 7.2 Europe Prostate Cancer Antigen 3 Test Consumption Value by Application (2019-2030)
  • 7.3 Europe Prostate Cancer Antigen 3 Test Market Size by Country
    • 7.3.1 Europe Prostate Cancer Antigen 3 Test Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 7.3.3 France Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Prostate Cancer Antigen 3 Test Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Prostate Cancer Antigen 3 Test Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Prostate Cancer Antigen 3 Test Market Size by Region
    • 8.3.1 Asia-Pacific Prostate Cancer Antigen 3 Test Consumption Value by Region (2019-2030)
    • 8.3.2 China Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 8.3.5 India Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Prostate Cancer Antigen 3 Test Consumption Value by Type (2019-2030)
  • 9.2 South America Prostate Cancer Antigen 3 Test Consumption Value by Application (2019-2030)
  • 9.3 South America Prostate Cancer Antigen 3 Test Market Size by Country
    • 9.3.1 South America Prostate Cancer Antigen 3 Test Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Prostate Cancer Antigen 3 Test Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Prostate Cancer Antigen 3 Test Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Prostate Cancer Antigen 3 Test Market Size by Country
    • 10.3.1 Middle East & Africa Prostate Cancer Antigen 3 Test Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Prostate Cancer Antigen 3 Test Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Prostate Cancer Antigen 3 Test Market Drivers
  • 11.2 Prostate Cancer Antigen 3 Test Market Restraints
  • 11.3 Prostate Cancer Antigen 3 Test Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Prostate Cancer Antigen 3 Test Industry Chain
  • 12.2 Prostate Cancer Antigen 3 Test Upstream Analysis
  • 12.3 Prostate Cancer Antigen 3 Test Midstream Analysis
  • 12.4 Prostate Cancer Antigen 3 Test Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    The prostate cancer antigen 3 gene (PCA3) test is used to assess your risk of developing prostate cancer. It is not used to make a diagnosis of prostate cancer. It is primarily used to determine whether your elevated prostate-specific antigen (PSA) levels are the result of prostate cancer. Prostate cancer is a type of cancer that develops in the prostate gland of men and is increasing at a significant rate each year. This cancer is commonly found in the elderly population, and it can have serious consequences such as blood in the sperm, bone pain, and erectile dysfunction, among others. As a result, early detection is required to avoid it at an early stage.
    According to our (Global Info Research) latest study, the global Prostate Cancer Antigen 3 Test market size was valued at US$ 53.2 million in 2023 and is forecast to a readjusted size of USD 95.2 million by 2030 with a CAGR of 8.9% during review period.
    The Global key players of Prostate Cancer Antigen 3 Test include Hologic, Thermo Fisher Scientific, MDxHealth, etc. The top three players hold a share about 77%. US & Canada is the largest market, and has a share about 37%. In terms of product type, RT-PCR is the largest segment, which occupied for a share of about 87%. For application, Hospital is the largest segment, which has a share about 61%.
    This report is a detailed and comprehensive analysis for global Prostate Cancer Antigen 3 Test market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
    Key Features:
    Global Prostate Cancer Antigen 3 Test market size and forecasts, in consumption value ($ Million), 2019-2030
    Global Prostate Cancer Antigen 3 Test market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
    Global Prostate Cancer Antigen 3 Test market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
    Global Prostate Cancer Antigen 3 Test market shares of main players, in revenue ($ Million), 2019-2024
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Prostate Cancer Antigen 3 Test
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Prostate Cancer Antigen 3 Test market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hologic, Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Copyright Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Prostate Cancer Antigen 3 Test market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segmentation
    Prostate Cancer Antigen 3 Test market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    RT-PCR
    ELISA Test
    Market segment by Application
    Hospital
    Diagnosis Center
    Other
    Market segment by players, this report covers
    Hologic
    Thermo Fisher Scientific
    MDxHealth
    Exosome Diagnostics GmbH
    Copyright Creative Diagnostics
    Lytech
    YUBO
    MicroDiag Biomedicine
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Prostate Cancer Antigen 3 Test product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Prostate Cancer Antigen 3 Test, with revenue, gross margin, and global market share of Prostate Cancer Antigen 3 Test from 2019 to 2024.
    Chapter 3, the Prostate Cancer Antigen 3 Test competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Prostate Cancer Antigen 3 Test market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Prostate Cancer Antigen 3 Test.
    Chapter 13, to describe Prostate Cancer Antigen 3 Test research findings and conclusion.

    Buy now